Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Return on Sales (2020 - 2025)

Historic Return on Sales for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 0.07%.

  • GeneDx Holdings' Return on Sales rose 400.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.17% for FY2024, which is 7000.0% up from last year.
  • According to the latest figures from Q3 2025, GeneDx Holdings' Return on Sales is 0.07%, which was up 400.0% from 0.11% recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Return on Sales ranged from a high of 0.76% in Q3 2021 and a low of 5.03% during Q4 2022
  • Its 5-year average for Return on Sales is 0.95%, with a median of 0.7% in 2021.
  • Per our database at Business Quant, GeneDx Holdings' Return on Sales tumbled by -43400bps in 2022 and then surged by 45800bps in 2023.
  • Quarter analysis of 5 years shows GeneDx Holdings' Return on Sales stood at 0.7% in 2021, then crashed by -624bps to 5.03% in 2022, then soared by 91bps to 0.45% in 2023, then skyrocketed by 113bps to 0.06% in 2024, then tumbled by -215bps to 0.07% in 2025.
  • Its Return on Sales was 0.07% in Q3 2025, compared to 0.11% in Q2 2025 and 0.07% in Q1 2025.